Marija Balic, Co-director of Magee Womens Cancer Program at University of Pittsburgh School of Medicine, shared a post on LinkedIn:
“Honoured to present our analyses of tumor informed based ctDNA analyses in NSABP B59 GeparDouze study in TNBC patients underground neoadjuvant chemotherapy +- atezolizumab. Post-surgery ctDNA + was associated with 30fold risk of recurrence. Thanks to all patients and in this case specifically to Exact Sciences for development of a very promissing Oncodetect assay and support of the substudy.”
You Can Also Read:
15 Posts Not to Miss from SABCS 2025, Part 1
20 Posts Not to Miss from SABCS 2025, Part 2
20 Posts Not to Miss from SABCS 2025, Part 3
